Fig. 1: mCherry-BCLXL colocalizes with the mitochondria and prevents BAX recruitment in vitro.
From: BCLXL gene therapy moderates neuropathology in the DBA/2J mouse model of inherited glaucoma
Representative images of D407 cells expressing mCherry (A–D), mCherry-BCLXL (E–H) along with mitoBFP and GFP-BAX 3.5 h after treatment with 1 µM staurosporine (STS). Note that mitoBFP fluorescence is rapidly lost when the mitochondrial outer membrane becomes permeabilized and the mitochondria become fragmented, which is why B has dramatically reduced fluorescence. Scale bar = 10 µm. Live cell imaging was used to track the localization of GFP-BAX for 3.5 h after STS treatment. The percentage of cells in each condition with punctate localization is quantified in I. N = 163 and 146 cells for the mCherry and mCherry-BCLXL expressing groups, respectively. χ2 test was used to assess the significance of the difference in percentage between each group at each time point. P < 0.0005 at 30 min, P < 0.00001 at 120 min, and P < 0.00001 at 210 min.
